Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Robotics in healthcare

  • 15 February 2021 (3 min read)


Robotic surgery has been around since the 1980s, with benefits that include enhanced dexterity, greater precision and control, lower infection rates and quicker recovery / shorter hospital stays. Advancements in technology and the medical field mean that robots can now assist in a variety of procedures, from general surgery to delicate operations (e.g. taking out brain tumours, heart and spine surgery, joint replacements etc.)

Stock examples

Intuitive Surgical

Company description: A leading provider of robotic surgery equipment.

Did you know: Intuitive Surgical’s robots performed 1.2 million surgical procedures in 2019, with this figure growing at around 15-20% per year.1

Zimmer Biomet

Company description: A US healthcare company that focuses on knee surgery.

Did you know: The global share of older people (60+) will increase by 42% from 2018 to 2030 – five times faster than the under 60 population.2

Knee joints run the risk of becoming worn or damaged over time, while much of the older generation now live more active lifestyles. This means more and more people may find they need knee surgery in their later years.

The investment case

Only 2% of surgery globally is currently done with robots. Most of this is in the US, but there is huge potential for geographic expansion in the coming years. Furthermore, medical robot sales are expected to achieve a CAGR of 30% between 2019 and 2023.3 Furthermore, there remains potential for an increase in the types of application; for example, the removal of tumours from parts of the body that would otherwise be difficult to reach.

Sources: All stocks mentioned are for illustrative purposes only and should not be considered as advice or a recommendation for an investment strategy.

  • SW50dWl0aXZlIFN1cmdpY2FsLCBhcyBhdCAzMSBEZWNlbWJlciAyMDE5
  • Qm9mQU1MIFNpbHZlciBEb2xsYXIgLyBMb25nZXZpdHkgcmVwb3J0IGZyb20gTWF5IDIwMTY=
  • SW50ZXJuYXRpb25hbCBGZWRlcmF0aW9uIG9mIFJvYm90aWNzIDIwMjA=

Have our latest insights delivered straight to your inbox

Subscribe to updates.

    Not for Retail distribution

    This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    This promotional communication does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee that forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Before making an investment, investors should read the relevant Prospectus and the Key Investor Information Document / scheme documents, which provide full product details including investment charges and risks. The information contained herein is not a substitute for those documents or for professional external advice.

    The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site https://www.axa-im.com/en/registration-map, where a fund registration map is available. In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor’s tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisors.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. 

    Are you an IFA or other Professional Investor ?

    Are you a financial advisor, institutional, or other professional investor?

    This section is for professional investors only. You need to confirm that you have the required investment knowledge and experience to view this content. This includes understanding the risks associated with investment products, and any other required qualifications according to the rules of your jurisdiction.